

**NOTIFICATION OF A PERSON  
ON THE ACQUISITION OF VOTING RIGHTS**

1. Akcinė bendrovė "Sanitas", code I34136296, Vytauto ave. 3, Kaunas, Lithuania

(name, code, registered address, home office address, State of the issuers)

2. The reasons for crossing the threshold (*specify the relevant reason*)

acquisition of shares from AB "Invalda"

(acquisition or a disposal of voting rights (*underline the necessary and indicate the specific reason*))

(acquisition or disposal of securities that subject to a formal agreement upon a request of the owner thereof grants the right to acquire in the future the shares already issued by the issuer (*underline the necessary and indicate the specific reason*)).

(the event resulting in the change of the number of the voting rights held (*indicate the specific event*))

3. Baltic Pharma Limited

(name and last name of the person who has acquired or disposed of the voting rights, or the name of the company)

4.

(name and last name of the shareholder, if different from the person indicated in item 3)

5. Date of the transaction (*enter*) and

28 October 2008

the date of which the threshold was crossed (*specify, if different*):

6. Threshold that was crossed or reached (*specify*):

75<sup>1</sup>

7. Data submitted:

Voting rights granted by the shares:							
Class of shares, ISIN code	Number of shares and votes held previous to the acquisition or disposal of the block of shares**		The number of shares and voting rights held at the date of crossing the threshold				
	Number of shares (units)	Number of votes (%)	Number of shares (units)	Number of voting rights (units)		Number of voting rights (%)	
			Directly	Directly	Indirectly <sup>2</sup>	Directly	Indirectly <sup>3</sup>
PVA,	-	-	1,555,296	1,555,296	24,116,261	5	77.53

<sup>1</sup> Threshold of 5% is crossed by direct acquisition. However, Baltic Pharma Limited has joined the existing group of persons acting in concert indicated in item 10; the group has votes exceeding the threshold of 75%.

\*\* Total votes and shares held (i.e. held directly and indirectly).

<sup>2</sup> Please see explanation in item 10. Information on number of voting rights (units) is based on the data taken from AB "Sanitas" consolidated interim report for the six months of the year 2008.

<sup>3</sup> Please see explanation in item 10. Information on number of voting rights (per cent) is based on the data taken from AB "Sanitas" consolidated interim report for the six months of the year 2008.

LT0000106171						
Total (A):		1,555,296	1,555,296	24,116,261	5	77.53

Data on the securities that subject to a formal agreement upon a request of the owner thereof grants the right to acquire in the future the shares already issued by the issuer.				
Name of securities	Date of expiry of the securities	The dates of conversion and (or) the exercise of the rights granted by the securities	Number of shares and votes to be acquired through the exercise of the rights attached to the securities (units)	Shares and votes to be acquired through the exercise of the rights attached to the securities (percent)
Total (B):				

Total number of votes held (A + B) <sup>4</sup>		
	Number of votes (units)	Number of votes (%)
Total:	25,671,557	82.53

8.

(the chain of controlled entities actually managing the voting rights and (or) securities that subject to a formal agreement upon a request of the owner thereof grants the right to acquire in the future the shares already issued by the issuer (to be completed if necessary).

9. The right granted to the proxy \_\_\_\_\_ to vote at his own discretion in  
(name and last name of the proxy)  
respect of \_\_\_\_\_ expires on \_\_\_\_\_  
(voting rights, units, %) (date)

10. Baltic Pharma Limited has joined the existing group of persons acting in concert, comprising of Citigroup Venture Capital International Jersey Limited, Amber Trust II SCA, AB "Invalda", Dalius Juozapas Mišeikis, UAB "Finasta" rizikos valdymas, UAB FMĮ "Finasta", AB bankas "Finasta", Darius Šulnis, UAB "Invalda turto valdymas", Tomas Nausėda, Jonas Bielinis, Nerijus Nausėda, Arūnas Tuma, Alvydas Dirvonas, Darius Žaromskis and Donatas Jazukevičius.

(additional information)

<sup>4</sup> Please see explanation in item 10. Information on number of voting rights (units and per cent) is based on the data taken from AB "Sanitas" consolidated interim report for the six months of the year 2008.

**ANNEX TO NOTIFICATION OF A PERSON  
ON THE ACQUISITION OF VOTING RIGHTS**

1.1. The identity of the natural or legal person obligated to submit the notification:

Baltic Pharma Limited, registration number: 218089

(name, last name, personal code or the name of the company, code)

Citigroup Venture Capital International Investment GP Limited, 26 New Street, St. Helier  
JE2 3RA, Channel Islands

(contact address)

Telephone: +44 1534 814 814, fax: +44 1534 814 815

(telephone, fax numbers; electronic mail address)

(other relevant information)

1.2. Identity of a contact person in case of any questions or inquiries in relation to the entity indicated in item 1.1:

Attorney-at-law Kęstutis Adamonis, Law firm Sorainen and partners, registration number:  
9400025

(name, last name, the name of the company, code)

Jogailos str. 4, LT-01116 Vilnius, Lithuania

(contact address)

Telephone: +370 5268 5040, fax: +370 5268 5041, e-mail address  
kestutis.adamonis@sorainen.lt

(telephone, fax numbers; electronic mail address)

(other relevant information)

2. Identity of the person submitting the notification (where the notification is submitted by a person different from that indicated in item 1):

(name, last name, personal code or the name of the company, code)


(contact address)

(telephone, fax numbers; electronic mail address)

(other relevant information)

3. By signing the present information notification I hereby confirm that the information presented therein is complete and accurate, and that I have familiarised myself with the

sanctions imposed for the provision of misleading information provided for in the Law on Securities and the Code of Administrative Violations of Law of the Republic of Lithuania.

  
Michael Richardson, Director of Citigroup Venture Capital  
International Investment G.P. Limited, in its capacity as the director of Baltic Pharma  
Limited, 4 November 2008, Jersey

(the signature of the person notifying of the acquisition or disposal of shares (name, last name and the signature of the manager of the company), the date of filling in the notification, place)